Figure 1

SVF CD14⁺cells exhibit a proangiogenic phenotype. PB nucleated cells (A) were analyzed for CD45 and CD34 expression. Top right, CD34⁺CD45^low cells corresponding to hematopoietic progenitor cells are shown. Bottom, CD45⁺ cells (blue) were gated and analyzed for CD14 expression and for co-expression of CD14 with CD31, Tie2, KDR, Flt-1, and CD34. The CD14⁺ cells represented 20% of CD45⁺ cells, which in turn accounted for 98.5% of the total viable PB nucleated cells. SVF cells (B) were analyzed for CD45 expression, and then the gated CD45⁺ cells (blue) were analyzed for CD34 and CD14 expression and for the co-expression of CD14 with CD31, CD144, Tie2, KDR, Flt-1, and CD34. Isotype-matched controls are shown. CD45⁺ cells accounted for 6% of total viable cells. Dot plots of CD14 conjugated with APC or PE correspond to three different samples.